Holen Sie sich die Stockscreener-App
8.96
3.94%
0.34
Handel nachbörslich:
8.92
-0.04
-0.45%
Schlusskurs vom Vortag:
$8.62
Offen:
$8.62
24-Stunden-Volumen:
2.08M
Relative Volume:
0.85
Marktkapitalisierung:
$885.48M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-44.84M
KGV:
-19.06
EPS:
-0.47
Netto-Cashflow:
$-44.23M
1W Leistung:
-1.65%
1M Leistung:
-10.85%
6M Leistung:
-35.86%
1J Leistung:
-39.13%
1-Tages-Spanne:
$8.4517
$8.98
1-Wochen-Bereich:
$8.4517
$9.655
52-Wochen-Spanne:
$8.4517
$18.90
Ars Pharmaceuticals Inc Stock (SPRY) Company Profile
Firmenname
Ars Pharmaceuticals Inc
Sektor
Branche
Telefon
858-771-9307
Adresse
11682 EL CAMINO REAL, SUITE 120, SAN DIEGO
Vergleichen Sie SPRY mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
SPRY
Ars Pharmaceuticals Inc
|
8.96 | 851.88M | 0 | -44.84M | -44.23M | -0.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.57 | 107.66B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
651.80 | 68.74B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
456.04 | 58.93B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
818.50 | 50.51B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
189.60 | 41.29B | 447.02M | -1.18B | -868.57M | -6.1812 |
Ars Pharmaceuticals Inc Stock (SPRY) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-09-04 | Eingeleitet | Roth Capital | Buy |
| 2025-03-07 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-02-10 | Eingeleitet | Oppenheimer | Outperform |
| 2024-08-20 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-13 | Hochstufung | Raymond James | Outperform → Strong Buy |
| 2024-08-12 | Bestätigt | Leerink Partners | Outperform |
| 2024-07-25 | Eingeleitet | Raymond James | Outperform |
| 2024-03-05 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-02-20 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2023-09-20 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2023-01-31 | Eingeleitet | Wedbush | Outperform |
| 2023-01-03 | Eingeleitet | William Blair | Outperform |
| 2022-12-13 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Ars Pharmaceuticals Inc Aktie (SPRY) Neueste Nachrichten
Why ARS Pharmaceuticals Inc. stock could outperform in 2025Market Sentiment Report & Short-Term High Return Strategies - newser.com
Why ARS Pharmaceuticals Inc. stock is recommended by analystsTrade Volume Summary & Growth Focused Investment Plans - newser.com
Published on: 2025-11-02 04:08:25 - newser.com
Will ARS Pharmaceuticals Inc. rebound enough to break evenGap Down & Advanced Swing Trade Entry Alerts - newser.com
Custom strategy builders for tracking ARS Pharmaceuticals Inc.Quarterly Profit Report & Free Technical Pattern Based Buy Signals - newser.com
Multi factor analysis applied to ARS Pharmaceuticals Inc.Earnings Recap Report & Expert Approved Momentum Trade Ideas - newser.com
How ARS Pharmaceuticals Inc. stock reacts to inflationary pressuresJuly 2025 Outlook & Precise Trade Entry Recommendations - newser.com
Why ARS Pharmaceuticals Inc. stock could rally in 2025Trade Entry Summary & Reliable Volume Spike Trade Alerts - newser.com
How ARS Pharmaceuticals Inc. stock trades during market volatilityGap Up & Daily Oversold Bounce Ideas - newser.com
Published on: 2025-11-01 01:27:58 - newser.com
ARS Pharmaceuticals (NASDAQ:SPRY) Hits New 52-Week LowWhat's Next? - MarketBeat
How ARS Pharmaceuticals Inc. stock valuations compare to rivalsWeekly Stock Recap & Low Drawdown Investment Ideas - newser.com
Trend analysis for ARS Pharmaceuticals Inc. this weekMarket Weekly Review & Momentum Based Trading Ideas - newser.com
Reversal indicators forming on ARS Pharmaceuticals Inc. stockWeekly Stock Summary & High Accuracy Investment Entry Signals - newser.com
Is ARS Pharmaceuticals Inc. stock supported by innovation pipelineJuly 2025 Catalysts & Community Trade Idea Sharing Platform - newser.com
Is ARS Pharmaceuticals Inc. a candidate for recovery playWeekly Stock Report & AI Forecasted Entry/Exit Points - newser.com
ARS Pharmaceuticals Hits New 52-Week Low at $8.90 Amid Financial Struggles - Markets Mojo
Ars Pharmaceuticals’ Latest Study: A Potential Game-Changer in Allergy Treatment - MSN
Can ARS Pharmaceuticals Inc. stock sustain revenue growthWeekly Stock Summary & Daily Risk Controlled Trade Plans - Fundação Cultural do Pará
Allianz Asset Management GmbH Makes New $639,000 Investment in ARS Pharmaceuticals, Inc. $SPRY - MarketBeat
Finanzdaten der Ars Pharmaceuticals Inc-Aktie (SPRY)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.62%
0.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):